Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsLiabilities and Shareholders EquityLong-Term Deferred TaxLong-Term InvestmentsNon-Current AssetsNon-Current DebtOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Retained EarningsShareholder's EquityTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Centessa Pharmaceuticals (CNTA) Long-Term Deferred Tax (2022 - 2025)

Centessa Pharmaceuticals (CNTA) has disclosed Long-Term Deferred Tax for 4 consecutive years, with $24.8 million as the latest value for Q4 2025.

  • Quarterly Long-Term Deferred Tax fell 6.8% to $24.8 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $24.8 million through Dec 2025, down 6.8% year-over-year, with the annual reading at $24.8 million for FY2025, 6.8% down from the prior year.
  • Long-Term Deferred Tax for Q4 2025 was $24.8 million at Centessa Pharmaceuticals, down from $25.0 million in the prior quarter.
  • The five-year high for Long-Term Deferred Tax was $29.6 million in Q4 2023, with the low at $3.5 million in Q4 2022.
  • Average Long-Term Deferred Tax over 4 years is $25.2 million, with a median of $26.7 million recorded in 2023.
  • The sharpest move saw Long-Term Deferred Tax surged 744.16% in 2023, then fell 11.27% in 2025.
  • Over 4 years, Long-Term Deferred Tax stood at $3.5 million in 2022, then soared by 744.16% to $29.6 million in 2023, then fell by 10.32% to $26.6 million in 2024, then fell by 6.8% to $24.8 million in 2025.
  • According to Business Quant data, Long-Term Deferred Tax over the past three periods came in at $24.8 million, $25.0 million, and $25.4 million for Q4 2025, Q3 2025, and Q2 2025 respectively.